Serotonin and Noradrenaline Reuptake Inhibitors (SNRI) updated on 07-01-2025

Eye defects

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15171
R62280
Benevent - SNRI, 2023 Eye malformations 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Monotherapy: SNRI only 2.45 [0.15;39.56] C 0/314   95/146,855 95 314
ref
S11684
R42944
Ankarfeldt a - Duloxetine (Controls unexposed, NOS), 2021 Eye malformations 1st trimester population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes Monotherapy: no or not specified 1.25 [0.46;3.41]
excluded (control group)
5/1,438   16/5,751 21 1,438
ref
S11685
R42960
Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Eye malformations 1st trimester population based cohort retrospective unexposed, sick Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) 0.63 [0.20;1.91] 5/1,434   8/1,435 13 1,434
ref
S11745
R43130
Huybrechts - Duloxetine (Controls unexposed, NOS), 2020 Eye Anomalies 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) excluded Adjustment: Yes Monotherapy: no or not specified 0.98 [0.14;7.01]
excluded (control group)
-/2,532   -/- - 2,532
ref
S11746
R43144
Huybrechts - Duloxetine (Controls unexposed, sick), 2020 Eye Anomalies 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) 1.00 [0.06;17.34] -/2,532   -/2,456 - 2,532
ref
Total 3 studies 0.79 [0.30;2.10] 108 4,280
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Benevent - SNRI, 2023Benevent - SNRI, 2023 2.45[0.15; 39.56]9531412%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021Ankarfeldt a - Duloxetine, 2021 1 0.63[0.20; 1.91]131,43476%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: low Huybrechts - Duloxetine (Controls unexposed, sick), 2020Huybrechts - Duloxetine, 2020 2 1.00[0.06; 17.34]-2,53212%ROB confusion: moderateROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: low Total (3 studies) I2 = 0% 0.79[0.30; 2.10]1084,2800.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.79[0.30; 2.10]1084,2800%NABenevent - SNRI, 2023 Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.45[0.15; 39.56]95314 -NABenevent - SNRI, 2023 1 unexposed, sickunexposed, sick 0.67[0.24; 1.91]133,9660%NAAnkarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 2 Tags Adjustment   - No  - No 2.45[0.15; 39.56]95314 -NABenevent - SNRI, 2023 1   - Yes  - Yes 0.67[0.24; 1.91]133,9660%NAAnkarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 2 Monotherapy   - no or not specified  - no or not specified 0.67[0.24; 1.91]133,9660%NAAnkarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 2   - SNRI only  - SNRI only 2.45[0.15; 39.56]95314 -NABenevent - SNRI, 2023 1 Unexposed sick   - intermediate history of illness/tre ...  - intermediate history of illness/treatment (3-12 months before pregnancy) 0.67[0.24; 1.91]133,9660%NAAnkarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 2 All studiesAll studies 0.79[0.30; 2.10]1084,2800%NABenevent - SNRI, 2023 Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 11745, 11684

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.27[0.54; 2.97]1164,2840%NABenevent - SNRI, 2023 Ankarfeldt a - Duloxetine (Controls unexposed, NOS), 2021 Huybrechts - Duloxetine (Controls unexposed, NOS), 2020 3 unexposed, sick controlsunexposed, sick controls 0.67[0.24; 1.91]133,9660%NAAnkarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 20.510.01.0